Viridian Therapeutics, Inc. VRDN Return on equity

Return on equity at other companies

AmgenAMGN

91.5%-7.7pp

Immunovant, Inc.IMVT

-64.8%+2.5pp

Vera TherapeuticsVERA

-71.3%+296pp

PVL

Palvella TherapeuticsPVLA

-34.2%—

RegenxbioRGNX

-137.6%-817pp

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

FAQ

What is Viridian Therapeutics, Inc.'s return on equity?

Viridian Therapeutics, Inc. (VRDN) reported return on equity of -65.7% in Q2 2026.

How has Viridian Therapeutics, Inc.'s return on equity changed year-over-year?

Viridian Therapeutics, Inc.'s return on equity increased by 0.2% year-over-year, from -65.9% to -65.7%.

What is the long-term trend for Viridian Therapeutics, Inc.'s return on equity?

Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s return on equity has grown at a -21.3% compound annual growth rate (CAGR), from -163.1% to -49.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.